南新制药连遭监管处罚

Core Viewpoint - Nanjing Pharmaceutical has faced significant setbacks due to regulatory penalties and ongoing investigations, leading to continued financial losses and a volatile stock performance [1] Financial Performance - Nanjing Pharmaceutical has reported net losses for four consecutive years since 2021, with a loss of 0.69 billion yuan in the first three quarters of this year [1] - Despite a brief surge in stock price due to restructuring expectations, the stock has since halved from its peak earlier this year, although it remains up over 40% year-to-date [1] Regulatory Issues - The Ministry of Finance has imposed a fine of 100,000 yuan on Nanjing Pharmaceutical for inflating revenue by over 24 million yuan through fraudulent shipping documents and misreporting academic promotion expenses of 37 million yuan [1] - The company's head, Zhang Shixi, has also been fined 50,000 yuan for his responsibility in these violations [1] - Additionally, the China Securities Regulatory Commission has initiated an investigation into the company's annual report disclosure violations [1]